A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Not yet recruiting
Biogen
Phase 4
2022-05-27
The primary objective of this study is to verify the clinical benefit of monthly doses of
aducanumab in slowing cognitive and functional impairment as measured by changes in the
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in
participants with early Alzheimer's disease.
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.
Recruiting
InSightec
Early Phase 1
2022-07-01
The purpose of this study is to assess the safety and feasibility of administering standard
of care monthly Aduhelm (Aducanumab) infusion therapy in combination with opening the
blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild
Alzheimer's disease (AD) or mild cognitive impairment (MCI).
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.
Recruiting
Ali Rezai
Early Phase 1
2022-07-01
The purpose of this study is to assess the safety and feasibility of administering standard
of care monthly Aduhelm (Aducanumab) infusion therapy in combination with opening the
blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild
Alzheimer's disease (AD) or mild cognitive impairment (MCI).
This preview shows a limited data set Subscribe for full access, or try a Trial
Last updated: February 5, 2026
mmary
ADUHELM (aducanumab), developed by Biogen, received accelerated approval from the FDA in June 2021 for Alzheimer’s disease. It remains under ongoing clinical trials, with market growth influenced by regulatory discussions, reimbursement policies, and clinical efficacy debates. The drug faces competition from other amyloid-targeting therapies and emerging treatments in the Alzheimer’s pipeline. Market projections estimate the global Alzheimer’s treatment market for amyloid-targeting agents will reach $8-12 billion by 2030, with ADUHELM capturing a significant share if regulatory and reimbursement hurdles are resolved.
What Is the Current Status of ADUHELM Clinical Trials?
Ongoing and Upcoming Trials
Post-approval studies: Biogen launched Phase 4 and observational studies to assess long-term safety, efficacy, tolerability, and real-world impact.
Efficacy and safety confirmation: Trials such as NCT04407511 and NCT04467475 continue to analyze cognitive decline and biomarker changes over longer periods.
Trial Results Since Approval
2022 and 2023 data from post-marketing surveillance show mixed results:
Reduction in amyloid plaques confirmed via PET scans.
Limited definitive evidence on slowing cognitive decline in broader populations.
Reports of ARIA (amyloid-related imaging abnormalities) in approximately 30% of patients, raising safety concerns.
Regulatory and Market Dynamics Impacting Trials
The FDA’s ongoing requirement for confirmatory trials has faced delays, with Biogen submitting data in late 2022; full approval relies on these results.
European regulatory agencies remain cautious, with some initially granting conditional approval and requesting additional data.
What Is the Market Analysis for ADUHELM?
Market Landscape
Leading amyloid-targeting drugs include Biogen’s ADUHELM, Lilly’s donanemab, and Eisai/Biogen’s lecanemab—each showing promise in clinical trials.
The Alzheimer’s treatment market was valued at approximately $7.2 billion globally in 2022, projected to grow at a CAGR of 9% through 2030.
Anti-amyloid therapies are expected to capture roughly 60% of this market, assuming regulatory and reimbursement support.
Market Penetration Potential
Market adoption depends on regulatory clarity, cost coverage, and demonstration of long-term benefits.
Biogen’s target population for ADUHELM includes early-stage Alzheimer’s patients diagnosed via biomarkers.
Estimated sales volume for ADUHELM is projected at $3-5 billion annually in North America, with additional gains in Europe and Asia.
Pricing and Reimbursement
The drug’s list price initially set at $56,000 per year in the US.
Further data from confirmatory trials are expected to influence broader acceptance and formulary listing.
Potential regulatory adjustments or restrictions could expand or limit market access.
The ongoing debate over clinical efficacy continues, with some analysts questioning whether amyloid reduction translates into meaningful clinical benefit.
Medium to Long-term Projections (2025–2030)
Research indicates amyloid-targeting drugs could generate a cumulative market value of $8-12 billion globally.
The growth rate depends on the approval of rival therapies, development of combination treatments, and advances in biomarker diagnostics.
Production scale-up, manufacturing improvements, and cost management will impact pricing and reimbursement strategies.
Challenges
Efficacy skepticism: Major regulatory bodies question the clinical benefits, which could impact approval status.
Safety concerns: ARIA and infusion-related adverse effects pose risks for broader adoption.
Pricing pressures: While high initial prices set a revenue ceiling, payers' reimbursement caps may suppress sales growth.
Key Takeaways
ADUHELM remains under active clinical evaluation, with ongoing studies to confirm its long-term safety and efficacy profile.
Market penetration will depend heavily on regulatory decisions, reimbursement policies, and demonstration of cognitive benefit beyond amyloid reduction.
The Alzheimer’s treatment landscape is competitive, with several therapies nearing or in the market, which could dilute ADUHELM’s market share.
Projected market value by 2030 for amyloid-targeting drugs globally is $8-12 billion, with ADUHELM likely capturing a significant share if clinical and commercial barriers are managed effectively.
Safety and efficacy debates, especially concerning ARIA risk and clinical benefit, remain central to ADUHELM's future success.
FAQs
What are the main safety concerns with ADUHELM?
ARIA (amyloid-related imaging abnormalities), including edema and microhemorrhages, occur in approximately 30% of treated patients, necessitating monitoring.
Will ADUHELM be approved in Europe?
European regulators have been cautious, with some issuing conditional approvals pending further data, influencing market access.
How does ADUHELM compare to other amyloid therapies?
It is similar in mechanism but faces competition from Lilly’s donanemab and Eisai/Biogen’s lecanemab, which have shown promising efficacy with different safety profiles.
What factors influence ADUHELM’s reimbursement prospects?
The demonstration of clinical benefit, safety profile, and cost-effectiveness data are critical for payer coverage decisions.
What is the outlook if confirmatory trials fail to show clinical benefit?
Regulatory agencies could revoke approvals, market share would decline, and investor confidence might diminish significantly.
Citations
[1] Biogen. ADUHELM (aducanumab) prescribing information. 2021.
[2] FDA. FDA grants accelerated approval for Alzheimer’s drug. 2021.
[3] MarketWatch. Alzheimer’s drug market forecast. 2022.
[4] ClinicalTrials.gov. Ongoing trials for ADUHELM.
[5] Biogen Annual Report 2022.
[6] CMS guidelines on coverage of Alzheimer’s drugs.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
